Terms: = Pancreatic cancer AND CARS, P49589, 833, ENSG00000110619 AND Treatment
29 results:
1. Chimeric Antigen Receptor T Cell Therapy for pancreatic cancer: A Review of Current Evidence.
Czaplicka A; Lachota M; Pączek L; Zagożdżon R; Kaleta B
Cells; 2024 Jan; 13(1):. PubMed ID: 38201305
[TBL] [Abstract] [Full Text] [Related]
2. pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
[TBL] [Abstract] [Full Text] [Related]
3. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Reni M; Giommoni E; Bergamo F; Milella M; Cavanna L; Di Marco MC; Spada M; Cordio S; Aprile G; Cardellino GG; Maiello E; Bernardini I; Ghidini M; Bozzarelli S; Macchini M; Orsi G; De Simone I; Rulli E; Porcu L; Torri V; Pinto C;
ESMO Open; 2023 Feb; 8(1):100777. PubMed ID: 36731325
[TBL] [Abstract] [Full Text] [Related]
4. Establishment of the diagnostic and prognostic nomograms for pancreatic cancer with bone metastasis.
Liu Z; Liu H; Wang D
Sci Rep; 2022 Oct; 12(1):18085. PubMed ID: 36302941
[TBL] [Abstract] [Full Text] [Related]
5. Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan.
Kubota S; Haraguchi T; Kuwata H; Seino Y; Murotani K; Tajima T; Terashima G; Kaneko M; Takahashi Y; Takao K; Kato T; Shide K; Imai S; Suzuki A; Terauchi Y; Yamada Y; Seino Y; Yabe D
J Diabetes Investig; 2023 Jan; 14(1):67-74. PubMed ID: 36281720
[TBL] [Abstract] [Full Text] [Related]
6. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract] [Full Text] [Related]
7. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
[TBL] [Abstract] [Full Text] [Related]
8. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID).
Brugel M; Letrillart L; Evrard C; Thierry A; Tougeron D; El Amrani M; Piessen G; Truant S; Turpin A; d'Engremont C; Roth G; Hautefeuille V; Regimbeau JM; Williet N; Schwarz L; Di Fiore F; Borg C; Doussot A; Lambert A; Moulin V; Trelohan H; Bolliet M; Topolscki A; Ayav A; Lopez A; Botsen D; Piardi T; Carlier C; Bouché O
Eur J Cancer; 2022 May; 166():8-20. PubMed ID: 35259629
[TBL] [Abstract] [Full Text] [Related]
9. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response.
Barrak D; Villano AM; Villafane-Ferriol N; Stockton LG; Hill MV; Deng M; Handorf EA; Reddy SS
Eur J Surg Oncol; 2022 Jun; 48(6):1356-1361. PubMed ID: 35016837
[TBL] [Abstract] [Full Text] [Related]
10. A novel staging system and clinical predictive nomogram for more accurate staging and prognosis of malignant pancreatic intraductal papillary mucinous neoplasms: a population-based study.
Zhang H; Gao C; Chen J; Wu S; Bai J; Yin T
J Transl Med; 2021 Dec; 19(1):525. PubMed ID: 34952605
[TBL] [Abstract] [Full Text] [Related]
11. Distal pancreatectomy with resection of the celiac trunk, right or left hepatic artery without arterial reconstruction (extended DP-CAR).
Egorov VI; Petrov RV; Amosova EL; Kharazov AF; Petrov KS; Zhurina YA; Kondratyev EV; Zelter PM; Dzigasov SO; Grigorievsky MV
Khirurgiia (Mosk); 2021; (10):13-28. PubMed ID: 34608776
[TBL] [Abstract] [Full Text] [Related]
12. Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms.
Liao T; Su T; Huang L; Li B; Feng LH
Scand J Gastroenterol; 2022 Jan; 57(1):85-90. PubMed ID: 34592854
[TBL] [Abstract] [Full Text] [Related]
13. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib treatment: A Retrospective Multicentre Study.
Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
[TBL] [Abstract] [Full Text] [Related]
14. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic pancreatic cancer.
Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
[TBL] [Abstract] [Full Text] [Related]
15. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment.
Lee YE; Ju A; Choi HW; Kim JC; Kim EE; Kim TS; Kang HJ; Kim SY; Jang JY; Ku JL; Kim SC; Jun E; Jang M
J Control Release; 2020 Oct; 326():310-323. PubMed ID: 32682905
[TBL] [Abstract] [Full Text] [Related]
16. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract] [Full Text] [Related]
17. Predictive value of gamma-glutamyl transpeptidase to lymphocyte count ratio in hepatocellular carcinoma patients with microvascular invasion.
Zhang H; Zhou Y; Li Y; Qin W; Zi Y; Liu Y; Qiu X; Xu H; Liao W; Huang Z
BMC Cancer; 2020 Feb; 20(1):132. PubMed ID: 32070301
[TBL] [Abstract] [Full Text] [Related]
18. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Jin L; Tao H; Karachi A; Long Y; Hou AY; Na M; Dyson KA; Grippin AJ; Deleyrolle LP; Zhang W; Rajon DA; Wang QJ; Yang JC; Kresak JL; Sayour EJ; Rahman M; Bova FJ; Lin Z; Mitchell DA; Huang J
Nat Commun; 2019 Sep; 10(1):4016. PubMed ID: 31488817
[TBL] [Abstract] [Full Text] [Related]
19. Hangzhou criteria are more accurate than Milan criteria in predicting long-term survival after liver transplantation for HCC in Germany.
Qu Z; Ling Q; Gwiasda J; Xu X; Schrem H; Beneke J; Kaltenborn A; Krauth C; Mix H; Klempnauer J; Emmanouilidis N
Langenbecks Arch Surg; 2018 Aug; 403(5):643-654. PubMed ID: 30120543
[TBL] [Abstract] [Full Text] [Related]
20. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
[TBL] [Abstract] [Full Text] [Related]
[Next]
